Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Leukemia drug dosing study aims to protect kids

NCT ID NCT03481881

First seen Jan 11, 2026 · Last updated Jun 23, 2026 · Updated 27 times

Summary

This study looks at how children with leukemia process common medicines like painkillers, diuretics, and antibiotics. Researchers will measure drug levels in the blood to better understand dosing. The goal is to make these drugs safer and more effective for kids. No new treatment is being tested.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PEDIATRIC ALL are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Duke University

    RECRUITING

    Durham, North Carolina, 27710, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

standard of care drugs (e.g., furosemide, tacrolimus, fentanyl)

What this could lead to

If successful, this could help doctors give safer, more effective doses of these drugs to children with leukemia.

What could go wrong

This is an observational study, not a treatment trial. It won't directly improve health, and results may not apply to all children.

Conditions

The condition(s) this trial relates to.

childhood acute lymphoblastic leukemia Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.